Home  |  About the Book  |  Table of Contents  |  Search  |  Order  |  Visit JCO  |  Visit ASCO.org
ASCO Educational Book; 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar content in this book
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barrett, A. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Barrett, A. J.

Leukemia Vaccines to Boost the Graft-versus-Leukemia Effect after Allogeneic Stem Cell Transplantation

A. John Barrett, MD

From the Allogeneic Stem Cell Transplantation Section, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland

Author's disclosure of potential conflicts of interest is found at the end of this article.

Address reprint requests to A. John Barrett, MD, National Heart, Lung, and Blood, 10 Center Drive, Building 10 CRC, Room 3E5330, Bethesda, MD 20814; e-mail: barrettj{at}nhlbi.nih.gov

Overview: The graft-versus-leukemia effect observed after allogeneic stem cell transplantation remains the strongest evidence in humans that leukemia can be eradicated by T cells recognizing peptide antigens presented by MHC class I and II molecules on leukemia cells. Here we describe these leukemia-specific antigens and the T-cell responses to them, summarize current progress with leukemia vaccines, and explore the possibilities for combining vaccines with allogeneic stem cell transplantation to enhance graft-versus-leukemia effects.